生物学的製剤に効果不十分は強直性脊椎炎患者におけるウパダシチニブの有効性と安全性: フェーズIII試験オープンラベル延長試験の1年結果
Arthritis Res Ther 2023; 2023;18;25(1):172 doi 10.1186/s13075-023-03128-1
The efficacy and safety of updacitinib in bDMARD-IR patients with AS were sustained through to one year in an open-label extension of the SELECT-AXIS 2 study.
Patients receiving UPA had sustained improvement in ASAS40, ASDAS LDA, ASDAS ID, total back pain, nocturnal back pain, and BASFI up to 52 weeks, regardless of whether they receive UPA or PBO in the first 14 weeks of the study.
Keywords:
